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From the Editor’s Desk
This is the last issue of 2017 and we enter the
New Year with a very well suited thematic
issue on “Quality Assurance in Laboratory”.
Accredited laboratories follow a highly stringent
compliance criterion of regulatory laboratory
standards, quality assurance systems, validation
protocol for diagnostic tests along with support of
highly effective laboratory information system to
guarantee quality of standards and reliability of
analytical data.

striving to provide this to our end users. With this
background, the current issue contains articles on
quality assurance being practiced in all sections
of the laboratory. The topics include: guide to use
Levy Jennings chart, quality assurance in frozen
sections, quality assurance in laboratory biosafety
and quality requirements for reporting sickling
haemoglobin to name a few. We also have the
pathology and radiology correlation article which
has become a favorite by the readers.

Successful quality assurance programmes provide
consistent test results with minimal chances of
error and being a College of American Pathologists
(CAP) certified laboratory we are constantly

We hope our readers enjoy the material as much as
we enjoyed putting it together…
Happy New Year 2018!

Levey Jennings Chart and Guide to use
Westgard Rules
Dr Syed Bilal Hashmi
Clinical Chemistry

Quality control (QC) results are used to validate
whether the instrument is functioning within predefined specifications, deducing that patient test
results are correct and reliable. Once the test system
is validated, patient results can then be used for
diagnosis, prognosis, or treatment planning. The data
obtained from the daily analysis of QC pools can be
plotted to create a visual analysis also known as the
Levey-Jennings or LJ chart. The expected analyte
concentration, the established target value (mean),
and the desired number of standard deviations are
drawn on the y-axis, and the days of the month
are drawn on x-axis. Lines run across the graph at
the mean, as well as one, two and sometimes three
standard deviations either side of the mean. This
makes it easy to see how far off the result was.
Rule
12s
13s
22s
R4s
41s
10x

In 1981, Dr. James Westgard and his associates
developed a multi-rule procedure for interpreting control
data. In short the Westgard rules specify the LJ chart.
These rules are QC rules to help analyze whether or not
an analytical run is in-control or out-of-control. Any
values violating Westgard rules will be either rerun or
rejected depending on the rule violated. There are six
basic rules in the Westgard scheme. These rules are used
individually or in combination to evaluate the quality
of analytical runs. It makes use of a series of control
rules for interpreting control data and also reduces
the false rejection and improves the error detection.
The formulation of Westgard rules were based on
statistical methods. They are also used to define specific
performance limits for a particular assay and can be used
to detect both random and systematic errors.

Interpretation
One control measurement exceeds ± 2SD limits
One control measurement exceeds ± 3SD limits
Two consecutive control measurements exceed ± 2SD limit
If there is at least a 4SD difference between control values within a single run
4th consecutive control measurement exceeding 1SD on the same side of the mean
When there are 10 consecutive controls on the same side of mean

Type of Error
Warning
Random
Systematic
Random
Systematic
Systematic

3

VOL. 43, ISSUE 3

DECEMBER 2017

Quality Assurance in Frozen Section Studies
Dr Arsalan Ahmed and Summayia Sohail
Histopathology

Correlation of Intraoperative and Final Diagnosis
Monitoring the correlation of frozen section
diagnosis and permanent section diagnosis is an
integral component of a quality assurance/quality
improvement program in histopathology. It provides
a very important measure of performance with
respect to frozen section diagnostic accuracy. It
is recommended that permanent section slides
should be analyzed with the accompanying frozen
section slides to establish if any discrepancy exists
(CAP checklist item ANP.10075). Each frozen
section disagreement (major) should be treated
as an event that requires investigation and action,
and discrepancies should be reconciled in the final
pathology report (CAP checklist item ANP.10100).
Local protocols should outline the process for
treatment of a major discordance.

Reasons for discordance and their reported relative
frequencies include:
l
l
l
l
l
l

Concordance
Deferral-Appropriate
Deferral-Inappropriate
Disagreement-Minor
Disagreement-Major

Correlation Results
l

l

l

l

4

Concordance – represents cases where frozen
section and permanent section diagnosis are in
agreement
Deferral rate - The number of cases where 		
frozen section diagnosis was deferred until final
diagnosis was reached on permanent section
Minor Disagreement/Discordance – represents
a small change in diagnosis but there is minimal,
if any, clinical relevance
Major Disagreement/Discordance – represents
a significant difference between the original
frozen section diagnosis and the one rendered
upon final diagnosis where potentially there is a
serious impact on the patient’s treatment or outcome.

25% to 45%
30% to 45%
30% to 38%
30% to 38%
6% to 8%
0.5% to 3%

A number of variables must be considered
when collecting and interpretating quality
assurance data on frozen section performance
as follows:
l

Differences in case mix potentially can account
for difference in diagnostic accuracy of frozen
section. It is recognized that certain frozen
section activities (e.g. Sentinel lymph node,
assessment of surgical margins) have a high
discordance rate.

l

Performance data will depend upon whether case
discordance (# discordance/ # frozen section
cases.) is calculated, or whether the number of
blocks (# discordance/ # of all individual frozen
sections) is utilized in the denominator.

l

Calculations of discordance can be based on
broad comparison of benign versus malignant or
more specific diagnostic terminology.

The Association of Directors of Anatomic and
Surgical Pathology (ADASP) have recommended the
following correlation categories.
l
l
l
l
l

Misinterpretation
Specimen sampling
Block Sampling
Technical inadequacy
Inadequate clinical data
Labeling errors

ADASP recommends an acceptable accuracy
threshold of three percent for intraoperative
consultation. In every month the data is recorded
as a quality indicator and the frequency of
discordance compare with its bench mark and
presented in sectional meeting and DQMC
(Departmental Quality and Mangagement
Committee).
Turnaround Time
Frozen section TAT has a critical impact on operative
management. The turnaround time target is 20
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minutes or less for single frozen section specimen,
measured from the time that the pathologist
receives a frozen section specimen to the time
that a diagnosis is reported to the surgeon .More
than 20 minutes is acceptable in cases where
more than one block is processed or more than
one specimen is received for the same patient.
Frozen section record is kept in the quality
indicator. The laboratory should be able to meet

the 20 minute time limit for at least 90 percent of
cases.
Monthly Evaluation of Frozen TAT
The monthly evaluation of frozen TAT is monitored
and recorded. The list is presented and discussed in
the departmental sectional meeting.This data is also
shown in DQMC meeting.

Performance Improvement Monitors in
Histology
Dr Arsalan Ahmed and Summayia Sohail
Histopathology

Turnaround Time
Turnaround time is the basic performance
improvement monitor throughout anatomic
pathology. The basic approach that can be used
to track TAT in histology, is to use specific time
“stamp” through the laboratory information system.
This approach requires an entry at the time, tissue
blocks are submitted or a special request is made,
and an entry when the slides are released from the
laboratory. With this approach, the actual TAT in
hours can be specifically determined and trended.
Quality of Histologic Sections
The quality of histologic sections would be
assessed by the pathologist receiving histologic
preparations. The supervisor and technologists
must work together to ensure that pathologist input
is meaningful and consistent. A quality assessment
form is designed and the pathologists are instructed
to indicate a specific problem using coded
comments and individual case numbers. This form
assists the histology laboratory in documenting
corrective action, in compiling summary reports by
defects and in detecting trends.
Lost Specimen
A lost specimen is defined as “the loss of surgical
pathology specimen that has occurred after the case
has been accessioned in the laboratory and that
prevents an adequate pathologist examination of that

specimen. The acceptable threshold for these events
was defined by ADASP as one in 3000 cases.
A tissue lost may occur at the time of grossing, at
the time of processing due to failure of completely
close cassettes, or loss of tissue blocks. Every effort
should be made to find or account for “lost” surgical
pathology specimens. The staff member discovering
the discrepancy will immediately inform to the
supervisor of Histology who in turn should notify
the pathologist and the incident is considered as a
non-conforming event and is documented on a lab
non- conforming event form.
Floaters
Floaters are the small piece of tissue that arises from
a source other than the case under examination.
Floaters mainly arise due to cross contamination
during grossing, embedding, Microtomy or staining.
Identification of floaters by the pathologist can be
tracked using the form or marked on a slide and
number of occurrences per total tissue blocks or
slides can be aggregated as a useful performance
improvement monitors.
The average rate of occurrence on prospective slide
review for participants in Q-probe studies were
0.6 percent of slides, 0.8 percent of blocks and 1.2
percent of specimen. Following steps can be taken to
reduce its frequency.
l

All instruments used in grossing e.g. forceps,
5
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l

l

scalpels and scissors should be cleaned after 		
every case.
Floatation bath at microtome stations should be
frequently cleaned, particularly following any
poorly processed tissue that explodes on the
water bath.
Embedding forceps must be carefully cleaned off
paraffin after every case.

Histology laboratories must provide high quality
services by enforcing a technical quality control
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system. This can only be achieved by providing
accurate, relevant, precise and comprehensive data,
which is applied to medical management of patients.
Any misdiagnosis or errors on reports can lead to
massive impacts on the quality of service and health
consequences to patients. Thus, laboratories must
follow quality rules and standards that are already
established. More so, the goal of quality management
in laboratories should be to ensure continuous
improvement which would guarantee quality service
and quality laboratory results to consumers.

Assay Standardization and Challenges Faced
by Laboratories
Dr Hafsa Majid
Clinical Chemistry

Accreditation bodies around the globe encourage
assays harmonization to not only improve quality
of care but also improve efficiency, patient
satisfaction, and overall clinical operations. As
numbers of clinical laboratories are expanding it
is becoming more important that test performed
by different laboratories are standardized. Patients
receiving care across a healthcare network expect
uniform laboratory services throughout and any
differences in results reported from two sites or
laboratories can create confusion for patients
and clinicians. For example, serum creatinine
performed at two different labs on a specific
sample should give similar results (within analytes
specific allowable error). In instances where
assays are not standardized due to non-availability
of primary reference materials, guidelines
recommend that the follow up should be done with
a single method and baseline be re-determined,
when assay or methodology is changed.
Method standardization directly affects result
accuracy which in turn affects patient’s outcome.
Ideally all methods should be completely
comparable, but that is not noted in practice and
intermethod differences can affect the clinical
decision making. In long term monitoring a
patient can change or switch hospital or the
laboratory which has a different method of
analysis for that specific analyte. Clinicians
need testing standardization to interpret results
6

properly. Seeing different results can be very
confusing to clinicians and can potentially
results in misinterpretation of laboratory results.
For example when multiple laboratories in a
country offer different cTn assays (I versus T
and new high-sensitivity versus contemporary),
misdiagnosis is a distinct possibility. Patient
diagnosed based on cTn-T assay cannot be
monitored with cTn-I assay.
Pathologists also face difficulties in interpreting
reports of samples sent to reference laboratories
for comparison when difference in methodology
exists. Two non-standardized assays can produce
different results. In such instances deriving
qualitative or concordance for comparison will be
helpful. Taking fecal calprotectin as an example
for non-standardized assay; a patient with
inflammatory bowel disease will have raised fecal
calprotectin performed by two different methods
with good concordance but the bias between
results of the two methods can be high.
The main aim of clinical laboratories is to
provide information that is useful to help medical
decision-making, allowing optimal patient health
care. The standardization of laboratory results
assuring interchangeability of results would
significantly contribute to improvements in health
care, since lab results performed in different
locations or times could be universally applied.
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Quality Assurance in Immunohistochemistry:
The Way We Do It
Dr Sabeehuddin Siddique and Dr Khurram Minhas
Histopathology

Introduction
Immunohistochemistry (IHC) is a method for
localizing specific antigens in tissue or cells based
on antigen-antibody recognition. It has become an
indispensible tool in today’s practice of surgical
pathology. The Histopathology section at Aga Khan
University Hospital Karachi has pioneered the use of
immunohistochemical stains in laboratory practice in
Pakistan and with the passage of time the number of
procured antibodies is increasing. On the other hand,
the accrediting agencies for clinical laboratories,
such as College of American Pathologists have
laid down stringent policies and guidelines for
standardization, quality assurance, quality control
and improvement of immunohistochemistry
techniques.
Steps in Immunohistochemical Testing
The factors affecting the quality of results in
immunohistochemistry include events spanning from
the identification of the specimen to interpretation
of the stain and then its assimilation into the final
report. But before delving deeper into the details of
quality assurance process in immunohistochemistry,
and the way we achieve it in our laboratory, it
is imperative to have a basic idea about how the
process of immunohistochemical staining works.
This entire process can be broadly divided into preanalytic, analytic and post-analytic phases.
Pre-analytic steps: In order to reduce the ischemic
time until fixation, the specimen should be
immediately immersed in a standardized fixative
(such as formalin) as soon as it is surgically removed.
Therefore, upon being received in the laboratory and
after accessioning, all the specimens are specifically
checked if they have been adequately placed in
formalin. Specimens received in other medium
are transferred into formalin to prevent further
autolytic changes. Use of non-formalin fixatives is
strongly discouraged, and there are only a handful of
exceptions to its use including Bouin’s solution for
testicular biopsies and Zenker’s solution for lymph
nodes.

During grossing, the specimen is visually examined
for suspicious areas which need to be sampled for
microscopic examination. In order to achieve optimal
and reproducible immunohistochemical staining, thin
tissue sections (usually less than 3mm in thickness;
and 2 x 2 cm in size) are submitted for processing
and cutting. During these processes, rigorous checks
are kept on the system to detect any fault that may
render the tissue block unsuitable for microscopic
examination and subsequent immunohistochemical
testing.
Analytic steps: Staining is the analytical part of
the immunohistochemical process. It encompasses
antigen retrieval (to recover tissue antigens that
may have been altered by improper fixation);
blocking of endogenous enzymes; application
of the primary antibody (that may or may not be
followed by application of secondary antibody);
use of chromogen to visualize antigen/antibody
complex; and visualization system, ending with
counterstaining. In our laboratory, all these
processes are performed on state of the art DAKO®
autostainers using DAKO EnVision® Kits.
Post-analytic steps: In post analytic phase, the
pathologist interprets the stains in context with
positive and negative tissue controls using bright
field microscopy. The observed results are analyzed
in conjunction with the light microscopic features
of the tumor and are then incorporated into the final
histopathology report.
Routine Quality Control; Use of Daily Controls
and Interpretations of Immunostains
The single best evidence that the antigen has been
adequately demonstrated in a particular tissue is to
look at the internal control. Internal control refers to
antigens present in the normal tissue structures of the
patient tissue being tested. Unfortunately, an internal
control may not always be present. To overcome
this issue, with each batch of immunohistochemical
stains that we run in our laboratory a set of positive
and negative tissue controls for a particular antibody
7
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are also applied. The stains, along with the respective
positive and negative tissue controls, are reviewed
by an experienced histopathologist before being
distributed. Any discrepancy observed is logged,
notified to other pathologists and corrective measures
are taken. In fact, the process of daily quality
control does not end here. After the distribution of
stains, each signing out consultant interprets the
immunohistochemical staining in conjunction with
the provided controls and in context with tumor
morphology. Table 1 highlights the key parameters
that may adversely affect the immunohistochemical
staining quality.
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External Quality Assessments; Participation in
Cap Survey Program

Besides having a stringent internal quality
assessment tools, Aga Khan Hospital Clinical
laboratories has also been participating in the
external quality assessment programs offered by
the College of American Pathologists. One such
program is The MK program of the American
College of Pathologists in which unstained tissue
sections are provided to our laboratory along with a
clinical history and specifications as to which stains
should be performed. After performing the relevant
immunihistochemical
Table 1: Key parameters that may have an adverse effect on staining quality
stains, a Consultant
Potential Adverse Effect
Monitor
histopathologist records
Temperature of processors, embedding
the stain results and
Antigen degradation due to excessive heat
centers and slide drying apparatus
a favoured diagnostic
interpretation based on
pH of antigen retrieval solution
Decreased immunoreactivity due to incorrect pH
history, the histologic
Temperature of antigen retrieval solution/ Failure to reach the optimal temperature
appearance and the
chamber
immunophenotype.
Checklist for automated instrument set-up Selection of incorrect protocol or failure to apply correct
These results are
reagents results in absence of desired immunoreactivity
shared with the college,
Use of reagents beyond the manufacturer’s expiration
Reagent expiration dates
which then sends a
date may result in inconsistent staining
summary report that
includes the interpretation of the referees as well as
statistics on the response of participants, stratified
Evaluation and Validation of new Antibody
by antibody preparation used. These materials
provide an excellent mechanism of external quality
Whenever a new antibody is introduced in our center,
assurance and a source of published benchmarks for
it is diligently evaluated, optimized and validated
reproducibility.
before being used for diagnostic purpose. The goal
of this process is to establish the optimal titration,
Quality Assurance Monitors
detection system and antigen retrieval protocol.
Once the antibody has been optimized, it is tested on
Besides continuous monitoring of the
laboratory tissue in order to determine the sensitivity
immunohistochemical staining processes, it is crucial
and specificity. Simple it may sound; this process
that the laboratory keeps track and record of various
can be quite cumbersome, especially if the optimal
quality indicators pertaining to this process. Our
dilution titer is not achieved even on repeated
laboratory is no exception to this rule. We not only
attempts.
periodically review the data inferred from these
records but are bound to share this information with
Validation of new Lot
the College of American Pathologists as a part of
our accreditation process. A few noteworthy of such
Each new lot of antibody must be validated
parameters are listed below.
before it is used in clinical assays. For an
established primary antibody that is performing
1. Repeat Slides: An inadequate
well, the laboratory need only stain a small
		 immunohistochemical stain may be the result of
series of tissues, including the routine
		 less than optimal tissue selection and/or
positive and negative controls. For new lots
		 processing, antibody failure or technical
of detection system reagents, a similar side		 failure. It is important for the laboratory to
by side comparison of the old and new lots
		 document all requests for repeat stains,
should be performed and recorded using series
		 the reason for the request, the corrective action
of monoclonal and polyclonal antibodies that
		 performed and the final outcome. Interaction
optimally test the specificity and sensitivity of
		 of the pathologist and technologist on a
the detection system.
8
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		 case-by-case basis is essential for successful
		troubleshooting.
2. Turnaround Time: Immunohistochemistry may
		 add significantly to the overall turnaround time
		 of surgical pathology or cytopathology case. As
		 these may be high profile cases, objective
		 monitoring of turnaround time, either
		 periodically through a retrospective audit or
		 prospectively through the routine use of time
		 stamps, is a useful quality assurance measure.
3. Audits of Pathology Reports: A retrospective
		 review of reports from cases utilizing
		 immunohistochemistry stains may provide
		 very useful information on the efficacy and
		 efficiency of ordering practices by the
		 pathologists as a group and individually. More

		 importantly, a review by a pathologist not
		 involved in the case can provide useful
		 feedback regarding the clarity and completeness
		of reporting.
Besides the aforementioned quality assurance,
management and regulation processes in
immunohistochemistry followed in our
laboratory, additional requirements have
been laid down by the College of American
Pathologists, for reporting the results of
predictive marker studies for breast cancer
(including ER, PR and Her2-neu. We strictly
adhere to these policies in order to produce
the optimal staining results, as it has major
implications in the management of disease.

Quality Assurance in Laboratory Biosafety
Syeda Kiran Zaidi
Clinical Microbiology

Laboratory safety is a vital part of total quality
assurance program of our laboratory. “Quality
assurance” is all the policies and systematic
activities implemented within a quality system and,
“Biosafety” is application of knowledge, techniques
and equipment to prevent personal, laboratory and
environmental exposure to potential infectious agents
or biohazards. Together, we can say Biosafety is all
the actions taken to improve the quality of work and
personal safety.

Risk Assessment
The backbone of the practice of biosafety is risk
assessment. While there are many tools available to
assist in the assessment of risk for a given procedure
or experiment, the most important component is
professional judgment. Risk assessments should
be performed by the individuals most familiar with
the specific characteristics of the organisms being
considered for use, the equipment and procedures
to be employed, and the containment equipment
and facilities available. Most healthcare workers are
familiar with biosafety levels we are working in.
Policies and Standards

Quality Assurance Cycle - Medical Laboratory
Image courtesy: Google Images

Every institute must have a safety policy which
should include:
1. A reporting hierarchy for
safety officers designated
to each area for monitoring
safety indicators
2. Reporting any incident
with a breach in biosafety
3. Regular audits of the
facility to inspect for safety
of the working environment Image courtesy: Google Images
9
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Policies provide a recommendation to uphold
the standards set by the institute as per EPA
(Environmental Protection Agency) Regulations,
Federal, Provincial and Local Regulations, Joint
Commission International and College of American
Pathologist Standards are also included. Laboratory
safety standards must include
l A chemical hygiene plan which covers all
		 the hazardous materials used in the section.
		 The Material safety data sheet (MSDS)
		 should list and give details of all chemicals
		 used in each department. Each employee
		 should be well-versed in responding to
		 biological and chemical spills, and use of
		 spill kits. Eye wash stations are checked
		 daily and on monthly basis to ensure proper
		working
l Blood borne pathogen standard which
		 includes universal precaution (Discussed
		 below) and vaccination and post-exposure
		prophylaxis.
l Personal hygiene especially hand washing
		 and keeping work garments free of
		biohazard.
l Disposal of used linen and hospital garments
		 for both patients and staff
l Disposal of sharps and biohazardous wastes
		 in appropriate containers and incineration or
		deep burial

Any safety issues should be discussed in meetings
held on regular basis. Moreover, monthly indicators
are also sent to the chief safety officer for review.
Knowledge of safe practices can be enhanced through
planned lectures and drills. Each employee working in
the laboratory must be aware of firefighting, location
and usage of fire extinguishers, fire alarms, and fire
rescue team numbers. There should be designated
assembly areas in case of fire or earthquake for the
workers of all departments to facilitate headcount.
Infection Control
Infectious diseases are a major risk to patients,
visitors and staff. Infectious diseases can be spread
through direct contact or the air.
l Blood borne pathogens include Hepatitis
		 B Virus (HBV), Hepatitis C Virus (HCV)
		 and Human Immunodeficiency Virus
		 (HIV). Exposure to a Blood-borne pathogen
		 is a risk for faculty and staff of health-care
		 facilities. Health Care Workers in hospital
		 setting are at high risk of acquiring Hepatitis
		 B viral infections. So immunizations are
10

		
		
		
		
		

offered to all employees at risk of these. A
full course of Hepatitis B vaccination
consists of three (03) injections at zero, one
and six months. All these three doses are
compulsory for the safety of employees.

Universal Precautions:
1. Follow Standard (Universal) Precautions:
		 Blood and body fluid from all patients must
		 be handled as if they were infected with a
		 Blood borne pathogen.
2. Wash hands: after removing personal
		 protective attire, before leaving the restroom,
		 after contact with blood/body fluids or after
		 handling contaminated items, before and
		after eating
Proper
handwashing
techniques

your hands and
Rub both of your
each fingers and
1 Wet
3 Rub
apply soap throughly 2 palms together
between fingers

your nails and
the back of the hand
hands with
hands with clean
4 Rub
5 Rub
6 Rinse
7 Dry
your palm
and between fingers
clean water
cloth or tissue

Image courtesy: Google Images

l Proper method for washing hands:
		 Using regular soap, running water, rub hands
		 10-15 seconds of friction. After rinsing, dry
		 hands and then turn off the faucet with the
		paper towel.
3. Personal protective equipment: Wear gloves
		 when expecting to
l Touch items or surfaces contaminated
			 with blood or other body fluids.
l Handle blood or other body fluids specimens.
l Come in contact with patient’s open skin
			lesions.
l Obtaining a blood sample.

Always wash hands after removing gloves. Wear
a face shield or a combination of a facemask and
protective eyewear when at risk of splash or spray
to the face. Apron or other barrier gown can protect
personal clothing when it is likely to become soiled
due to splashes; if penetrated by blood or body fluid,
remove it as soon as possible.
4. Needle stick injuries (NSI)/sharps injury/
		 mucosal exposures to blood and body fluids
		 are hazardous to your health. If injured, put
		 the area under running water until it stops
		 bleeding. Wash the site with soap and water,
		 dry and cover with bandage. Trace patient’s
		HIV, HBV, HCV status and notify the safety officer.
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Quality Control of Culture Media Used in
Clinical Microbiology
Sobia Noshad Baig
Clinical Microbiology

The reporting of culturable
microorganisms, bacteria or
fungus, depends upon the quality
and sterility of the cultural media.
The quality and quantity of media
directly affects the observations
and results. Different parameters
of media such as poor growth
support, physical characteristics
and batch contamination can
result in false reporting. The
less quantity of media agar or
supplements also results in poor
growth. There are different
methods of checking all these
parameters systematically.
Culture media plays an essential role in the
clinical microbiology laboratory. The isolation of
microorganism is the prerequisite for identification
and sensitivity of pathogenic and nonpathogenic
organisms. Most laboratories prepare their
own culture media for routine diagnosis and for
research purpose. For ensuring the culture media’s
quality, quality control strains and materials are
set simultaneously to assess the complete range of
purpose for which the media is used. The batch of
media agar and broth prepared is thus considered fit
for use only after passing through rigorous quality
checks.
Raw Material
The quality of the culture media depends directly
upon the quality of the raw materials used for
preparation.

Only distilled water is used for the preparation of
cultural media. The water pH should be monitored
daily, and should be slightly acidic to neutral but
no lower than 5.5, as highly acidic pH may inhibit
the growth of microorganisms.The petri dishes used
for pouring of culture media should be ethylene
oxide (EtO) sterilized or gamma irradiated. Only
borosilicate glassware should be used because soda
glass can leach alkali into the media and change
its characteristics. There are various supplements
used in preparation of culture media including
supplements for enrichment, e.g. blood, NAD,
hemin and certain vitamins, and other inhibitory
additives, like antibacterial and antifungal agents
etc. Traditionally, animal blood should be used e.g.
sheep or horse, in most blood containing media, but
human blood has also been used with acceptable
results. Blood is collected aseptically and inoculated
in agar media after cooling to 50oC so that it doesn’t
denature. For additives purchased as prepared
supplements, the certificate of analysis and sterility
and temperature at the time of addition are important
considerations.
Sterilization
Sterilization plays an important role in the quality
of the culture media. Generally, for media with heat
stable components, autoclave is used for sterilizing
the culture media. However, the time of autoclaving
and the quantity of culture media sterilized should
be closely regulated. The standard autoclaving cycle
is maintained at temperature 121°C for 15 minutes
and 15 psi pressure. Overheating of bacterial media
can cause nutrient destruction, so temperature and
pressure timings are very important.
The volume of the bacterial media in sterilization
batch should be kept small, ideally two liters.
Sterilization process indicators should be checked
regularly. Temperature and pressure should also be
plotted while the autoclave is running so that it can
be monitored live. Records of biological indicators
(e.g. spore strip or bromthymol purple broth with
Geobacillus stearothermophilus spores) and chemical
and steam penetration indicator (e.g. Bowie Dick
11
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test) to check the efficiency of the process must be
maintained.

Cracked media.

EZ TEST (Biological indicator):
Bromthymol purple broth with
Geobacillus stearothermophilus spores.
VIOLET (Sterilized), YELLOW (Unsterilized)

BOWIE DICK STRIPS DARK BROWN – lower
strip (Poor steam penetration), BLACK- upper strip
(Good Steam penetration)
Physical appearance
The gross physical appearance of bacterial media
often shows the quality of media pouring. Prepared
bacterial media should be screened for physical
characteristics such as excessive bubbles or pits,
unequal filling of plates (non-uniform levels),
thickness of medium in the plate, which must be 4.0
± 0.2 mm, cracked and frozen or crystallized medium
in plate.
All the above
mentioned
characters can be
checked visually
by naked eye.

Excessive bubbles in media.
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The pH of the medium is also an extremely
important physical characteristic, which must be
checked. It can be measured after autoclaving of
media by using the standard pH meter after proper
calibration with standard buffers.
Microbiological parameters
Growth support is the most important parameter
while conducting quality control of media. Standard
inoculating procedures should be used, it includes
positive control and negative control. National
Committee for Clinical Laboratory Standards
(NCCLS) has laid down certain guidelines for the
control organisms to be used for every medium, the
desired inoculum concentration and their expected
growth results. After inoculation, the plates are
incubated at 37°C for 24 hours and their growth
and colony characteristics are observed. The results
can be reported by mentioning presence or absence
of growth and the growth characteristics. The
results should be examined both qualitatively and
quantitatively. While testing new lots, both previous
batch and new batch should be simultaneously
inoculated.
Contamination
This is a crucial parameter for the determination of
the quality of media. The batch must be checked for
contamination before passing for laboratory use. It is
also suggested that the whole batch of the prepared
media be checked for contamination by keeping the
plates at least for three days at room temperature in
case of a small batch (<100 plates). Alternatively,
5-10% of plates from the test batch can be taken and
placed into the incubator set at 37°C for 24 hours.
After required incubation, the plates are checked
for any growth. If there is any growth, the sterility
of the batch is rechecked, taking double the number
of plates from the same batch. If contamination is
confirmed in more than 10% of the incubated plates
from the batch, the media must be discarded, as per
recommendations.

VOL. 43, ISSUE 3

DECEMBER 2017

Conclusion

Contaminated culture plates

The quality control (QC) of bacterial media used in
clinical microbiology laboratory remains critical for
accurate and acceptable isolation of pathogens from
infected patients. Reference strains must be used as to
assess whether the media is behaving as expected for
both bacterial isolation, identification and sensitivity
testing, before releasing the batch for use in the
laboratory. Testing media using standard protocol can
save time and resources and ensure reliable reporting.

Quality Assurance (QA) in Qualitative Tests in
the Clinical Laboratory
Najma Shaheen
Clinical Microbiology

Quality Assurance is a way to achieve quality
service. In the clinical diagnostic laboratory it
ensures that laboratory processes are controlled
at every stage and the results generated by the
laboratory are accurate, reliable, timely and
reproducible.
Infectious diseases serology is an important diagnostic
modality because it provides analysis of disease
without any invasive intervention with a limited span
of time. These tests are qualitative semi-quantitative
and quantitative. For better and accurate result
interpretations, vigilant test procedure is required.
However, the laboratories especially in resource
limited countries have questionable reliability of
infectious serology results due to noncompliance with
the quality procedure and practices. Use of unreliable
diagnostic kits without performing proper quality
assurance is one of the major limiting factors for
reproducing good quality report.
Components of Quality Assurance
Pre-analytical:
1. Sample collection:
		 Sample must be collected in assigned
		 appropriate tube/container and should be
		 rejected if received in wrong container or
		wrong labeling.
2. Sample transportation:
		 Recommended condition for sample
		 transportation must be followed like

		 maintaining temperature and adding
		 preservative if there is any delay in
		transportation.
3. Sample processing:
		 Before performing the quality of specimen
		 must be assessed visually (Hemolysed,
		 lipemic or turbid sample).
		 The test sample must be processed according
		 to kit manufacturer’s instruction.
Analytical:
1. Method validation
		 Before starting to use any diagnostic kit,
		 the following important points must be taken
		 into consideration by the users.
l Use those kits whose manufacturer is well
		 known and reliable in diagnostic products.
l Diagnostic kit should be approved by some
		 reliable international quality assurance
		 agencies. (FDA or CE marked)
l Do not use kits which are intended for
		 research purposes only.
l Ensure thorough literature review and
		 market search before selecting any kit.
		 Laboratories can select those manufacturers
		 whose kit is in use by majority of peers if
		 you are a participant of a Proficiency testing
		 program (e.g. Proficiency testing by College
		 of American Pathologist -CAP).
Once selection has been done and kits received in
the laboratory, following quality assurance (QA)
13
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parameters must be performed as a validation and
verification process. Validation process must be
repeated if there is a change in methodology or
manufacturer.
a. Sample selection: To validate a diagnostic
		 kit known positive and negative samples are
		 required. Proficiency test samples (CAP
		 surveys) can be used for this purpose.
		 Well characterized positive clinical samples,
		 having relevant clinical history of that
		 disease and rechecked with authentic
		 methodology by some other laboratory with
		 better quality assurance process can also be
		used.
b. Number of samples required: 10-20
		 positive and 10-20 negative samples or well
		 characterized samples is the minimum
		 requirement for verification process of FDA
		 approved tests. For non-FDA approved or
		 modified FDA approved tests, the sample
		size is much larger, comprising 100-150 data points.
c. Accuracy: this parameter tells us that how
		 much our method is accurate to generate
		 the result, if we are running a sample of
		 known concentration. It is calculated by:
			 Accuracy=No. of correct results/ total
			 no. of results x 100
d. Precision: it means how precise our method
		 is, and can we get the same result upon
		 repeating. It is achieved by testing same
		 sample numerous times at different days
		 by different individual under the same
		 operating conditions. It is performed to
		 determine intra-run assay and inter-run assay
		 variation. Precision can be determined by:
			 Precision= No. of repeated results in
			 agreement/ total no. of results x 100
e. Specificity: it is the ability of method to
		 detect only the analyte of interest in the
		 presence of other factors “Specificity” can
		 be defined as the ability of the method to
		 specifically separate the particular analyte in
		 the presence of other components.
			 Specificity= No. of true negative results/
			 (No. of true negative results + No. of
			 false positive results) x 100
f. Sensitivity: it is the ability of method to
		 detect smallest quantity of analyte.
		 Selectivity refers to the ability of the method
		 to discriminate a particular analyte in a
14

		 complex mixture without interference from
		other components
			 Sensitivity: No. of true positive results /
			 (No. of true positive results + No. of
			 false negative results) x 100
g. Positive predictive value: it is performed to
		 check the probability that a patient with a
		 positive test result has the disease or the
		 presence of an analyte in a specimen
			 PPV=No. of true positive results / (No.
			 of true positive results + No. of false
			 positive results) x 100
h. Negative predictive value: it is performed
		 to check the probability that a patient with a
		 negative test result does not have the disease
		 or the absence of an analyte in a specimen.
			 NPV=No. of true negative results /
			 (No. of true negative results + No. of
			 false negative results) x 100
2. Quality Control-(Performance and documentation)
		 Kit’s commercial controls and internal
		 controls must be checked daily along with
		 the patients’ samples.
		 Results should be documented in designated
		 forms and must be reviewed periodically
		 (daily by bench in-charge and monthly by
		laboratory manager/consultant).
		 In case of erroneous quality control results,
		 patient sample results must be held back
		 and the cause evaluated. Repeat the tests by
		 alternative kit (same manufacturer and
		 same lot or same manufacturer with alternate
		 lot if available). If problem persists,
		 promptly coordinate with senior laboratory
		management.
3.
		
		
		
		
		
		
		
		
		
		
		
		
		
		

Equipment maintenance:
Equipment maintenance is scheduled as
daily, weekly, biannually or annually.
This schedule must be defined and
documented for all instruments and
coordinate with the defined protocols
and the designated person who will perform
that maintenance activity.
Equipment maintenance include daily
cleaning of instrument, calibration (if
required) before initiating to run the clinical
sample. If there is any error or nonfunctional
instrument or component, coordinate with
biomedical department or inform laboratory
manager if instrument is in warranty period.
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4. Lot-to-Lot verification :
		 Whenever new lot of any kit is received
		 it must be verified before performing on
		patient’s sample.
		Post-analytical:
1. Review of results:
		 All results are reviewed by consultant before
		 reporting to the patient
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2. Audits:
		 Internal and external audits are performed at
		 different interval to ensure compliance with
		 national and international guidelines.
3. Reference ranges: In case of quantitative
		 tests, reference ranges must be provided on
		 patient’s final report so that it can be helpful
		 for the treating physicians to interpret the
		result cautiously.

Overcoming Challenges in Quality Assurance:
Antimicrobial Susceptibility Testing by an
Automated System
Asima Shahid Sabzwari
Clinical Microbiology

Quality Assurance ensures systematic monitoring
and evaluation of the various aspects of a project,
service, or facility to ensure that standards of quality
are being met. Maintaining Quality Standards in
Antimicrobial susceptibility testing is an important
tool to ensure that the results are being correctly
delivered to the patients.
For maintaining Quality Assurance of a certain
automated testing system, there are certain elements
which must be kept in mind when drawing up an
Individualized Quality Control Plan (IQCP). These
key elements are Specimen, Reagent, Environment,
Testing Personnel, and Test System. All issues to
be monitored can easily be distributed under these
parameters and can thus be monitored accordingly,
with preventive actions in place, anticipating any
errors. If anything new comes up, a tailored preventive
action can be added to the IQCP under the above
categories and monitored. Each anticipated problem
can be given a risk grade according to the seriousness
of the problem. The main elements of IQCP include
Risk Assessment, Quality Control Plan and Quality
Assessment. An IQCP for the entire process must
address the failures and errors in Pre Analytic,
Analytic and Post Analytic phases of testing.
Risk Assessment
Risk Assessment is based on five elements Specimen,
Test system, reagent, environment and testing
personnel, and laboratory must ensures that all these

five parameters are covered in the Risk Assessment
plan.
l Specimen quantity should be acceptable
		 according to the manufacturer’s instructions
		 otherwise inadequate quantity of specimen
		 can cause false positive results and can cause
		 kit reagents to perform improperly. Reagent
		 integrity and expiration date needs to be
		 checked before patient testing. Each lot
		 should be verified before setting up
		 susceptibilities, and reagents and kits
		 should be stored in scientific grade
		 refrigerator. QC is performed weekly to
		 monitor effect of transient temperature
		 fluctuations on the integrity of each analyte
		 and performance of each equipment.
l Instrument diagnostics for temperature and
		 optics fail which lead to frequent
		 terminations and error. Dust from uncovered
		 surfaces may interfere with the optics
		 causing power failures and affects
		 instrument. To prevent this, instrument
		 should be kept in areas with less dust fallout,
		 optics cleaned after frequent intervals and
		 regular instrument maintenance is required.
l Training of staff is also necessary because
		 if staff is not trained for setting up
		 susceptibilities, incorrect results will be
		 reported. Competency assessment and sign
		 off by trainer of all staff must be completed
		 before carrying out procedure on clinical
		 specimens. Adherence to Patient Safety 		
15
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Goal #1 deserves special mention
here; matching the Name and Laboratory
/ Medical Registration Number is of
foremost importance as there is zero
tolerance for this error.

Quality Control Plan
The Quality control plan should have certain
parameters that include:
l Error Detection: if an error occurs before
		 during or after testing it should be detected
		immediately
l It should specify the number, type and
		 frequency of Quality control material to be
		tested
l QC acceptable ranges should be defined
l QCs performed should be according to the
		 manufacturer’s instructions, no less
l Indicate that your laboratory director has
		 reviewed, signed and dated the QC plan
		document
Quality Assessment
Quality assessment can be monitored by considering
following aspects:
l There should be a record of Temperature
		 logs for room temperature, refrigerator and
		 freezer to ensure that temperature is being
		 monitored on daily basis. Instrument ambient
		 temperature can be affected if there is failure
		 of engineering controls over air conditioning
		 so this should be monitored by engineering
		 department servicing lab. Since the test
		 results are accepted as long as the QC
		 remains within the acceptable range,
		 ensuring the quality and integrity of the QC
		 material is supreme for the analytic phase.

l If Quality control fails, results on patient
		 samples are unacceptable or unreportable
		 if no obvious cause is found. This can
		 happen if Quality control ATCC strains
		 are not pure, too old or too young QC
		 cultures are used (correct age is 24-hour old
		 colonies), incorrect control strains are used
		 for the test, or inappropriate media is used
		 for revival of QC strains. To avoid such type
		 of errors, ATCC strains are revived weekly
		 according to a standard ATCC maintenance
		 plan, and all strains are saved at -80
		 degrees Celsius in a separate freezer box to
		 ensure conservation of their genotype/
		phenotype.
l Quality control log should also be 		
		 maintained and reviewed regularly to
		 ensure that corrective action has been taken
		 for any unacceptable values
l Manufacturer’s instructions should be
		 reviewed with each new lot or shipment and
		 if there is any change it should be updated in
		the policy
l Review of Personnel competency records
		 should also be done

Quality Assurance can be maintained by
following all the standards stated above. Our
experience with the IQCP for automated AST
(Vitek 2 system) has so far been very useful
in ensuring correct reporting of results. Any
inconsistencies or errors are analysed and if
necessary, the IQCP is revised to include new
occurrences or reduce the risk level of previously
addressed issues. We have been following all
these standards and performing quality control on
weekly instead of daily basis since almost 2 years
and are able to report automated susceptibilities
with confidence.

Radiology Pathology Correlation
Dr Nasir Ud Din and Dr Dawar Khan
Histopathology and Radiology

A 14 year old boy presented with progressive pain
in right leg, which was more at nights, and relieved
by taking non-steroidal anti-inflammatory drugs
(NSAIDs). A plain x-ray was performed followed by
16

computerized tomography (CT) scan. The CT scan
showed a radiolucent nidus surrounded by sclerotic
bone (Figure 1A,B). Resection of the nidus with
surrounding bone was done.
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Histopathologically, the nidus was composed of
multiple fragments of haphazardly interanastomosing
trabeculae of variably mineralized woven bone with
osteoblastic rimming. The intertrabecular stroma is
fibrovascular (Figure 2A,B). The surrounding bone
was thick sclerotic. A diagnosis of osteoid osteoma
was made based on radiological and histological
features correlation.

A

B

Figure 1A, B. CT coronal and axial images shows focal cortical thickening along a small lytic area and a nidus in proximal tibia.

A

B

Osteoid osteoma is a benign bone forming
lesion most frequently seen in children and
young adults and has a peak incidence in
the second decade of life. There is a male
predilection. The tumor most commonly
involves long bones of distal extremities,
particularly femur neck.
Clinically, the most common presentation is
pain of several months’ duration seen is 80
percent of patients. The pain is intermittent
at first, then becomes relentless and is more
severe at night. Aspirin and other NSAIDs
are very effective in alleviating the pain for
several hours at a time. The pain is believed to
be elicited by high levels of prostaglandin E2
and prostacyclin found within the nidus.
Radiological differential diagnosis of
osteoid osteoma is osteoblastoma, brodie’s
abscess, cortical stress fracture, and bone
island. Histologically, the closest differential
diagnosis is osteoblastoma. The characteristic
pattern of nocturnal pain in osteoid osteoma
is not seen in osteoblastoma and these tumors
preferentially involve the axial skeleton.
The diagnosis of the two tumors is made by
correlating overall clinical, radiological,
and histopathologic features. In borderline
cases, an arbitrary size cutoff of 1.5 cm has
historically been used.

Figure 2A, B. Histological examination of osteoid osteoma nidus shows
interconnecting trabeculae of woven bone with fibrovascular stroma

Identifying Problems before Proficiency
Testing Fails
Dr Lena Jafri
Clinical Chemistry

Proficiency testing (PT) is the external component
of quality control since it involves peer review.
It primarily measures accuracy because each
laboratory’s results are compared to the interlaboratory
or peer group mean, which is assumed to be the true
value. The graphs in PT evaluation reports can be
helpful in identifying problems even before PT results
become unacceptable or before incorrect patient
results are released.

Utilizing SDI for diagnostic interpretation of PT
survey report
Proficiency test results are reported as standard
deviation indexes (SDIs). This index represents
the number of standard deviations each result is
from the peer group mean. The SDI is calculated
by the following formula: SDI = (your result interlaboratory mean)/ interlaboratory SD. The
17
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best way to detect problems is to examine these
SDI results critically in PT evaluation reports. The
following rules are useful in evaluating SDI results:
l Do two or more of the five SDI results
		 exceed +/- 1? If not, a significant error is
		 unlikely and evaluation is complete. If so,
		 further questions need to be asked.
l Atleast one result exceeds +/- two SDI:
		 review results to rule out possible problems,
		 identify possible errors from non-analytical
		 sources for results with very high SDIs.
l The average of the five SDI results is more
		 than +/- 1.5: indicates significant bias
		 (systematic error) , calibration data should
		 be reviewed to determine if a shift has
		 occurred. Bias can usually be eliminated by
		recalibration.
l One PT result is more than +/- three SDI :
		 there is a high probability of random error.
l The range of SDI between the largest and
		 smallest PT result exceed 4 SDI: random
		 error is a possibility and the procedure
		 should be evaluated for potential sources of
		imprecision.
Allowed Deviation and Patterns in PT Evaluation
Graphs
The PT evaluation report also includes graphical
summary using the relative distance of your results
from the target. This distance is called the allowed
deviation. Allowed deviation is calculated by
subtracting the target value from your laboratory
result and dividing this difference by the PT
allowable error for that analyte. The ratio is then
multiplied by 100 to bring the value on a percent
scale ranging from -100 to +100. If results are
beyond -100 to 100 ‘x’ appears on the report
indicating that results exceed the graphical limit.
Monitoring PT graphs and rules using allowed
deviation has also been useful in identifying
problems before PT fails.
Patterns in PT Graphs for a Single Mailing/ Single Survey:
l One result in a mailing exceeds +/- 75
		 percent of the allowed deviation: review
		 results to rule out possible problems, identify
		 possible problems from non analytical
		 sources such as clerical errors for results that
		 exceed +/- 100% of the allowed deviation.
l All results are on one side of the target
		 values with atleast one difference exceeding
		 +/- 50 percent of the allowed deviation:
		shows bias indicating a possible calibration drift .
l Large positive and negative differences;
		 combined lengths of longest positive and
18

		 negative bars is >140 out of total range of
		 200: depicts random error
Patterns in PT Graphs over Multiple Mailings:
l Persistent results on one side of the target
		 values: shows persistent bias, even if small,
		 recalibration should have occurred within
		 this time frame.
l Results flip from one side of target to the
		 other (Figure 1): shows impact of system or
		 process changes, longer bars are of more
		 concern. Follow suggested action for
		systematic errors.
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Figure 1: Results flip from negative to positive bias.
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Over time, length of bars increase (Figure 2):
a sudden shift may show impact of system
or process changes, most likely random
error, may reveal new source of either
systematic or random error.
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Figure 2: Lengths of bars increase over time on both sides.
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Over time length of bars increases primarily
on one side (Figure 3): depict persistent bias,
take corrective action for systematic error.
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Figure 3: Lengths of bars increase over time on one side of target mean.
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Over time, length of bars decreases: shows
impact of system or process changes,
particularly as a result of corrective action.

Sometimes by reviewing results from multiple PT
mailings or surveys, performance trends that could
lead to PT failures are easily recognized and rectified.
For example graphical plots by College of American
Pathologists PT evaluation reports can identify trends
that would be missed without reviewing multiple PT
events together. As discussed above reviewing PT
results carefully over time can identify persistent bias,
trends, and shifts, change in system and/or process,
systematic error, evidence of corrective action,
training opportunities and staff competencies.
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Quality Requirements for Reporting Sickle
Haemoglobin
Dr Nazish Sana and Dr Muhammad Shariq Shaikh
Haematology & Transfusion Medicine

The haemoglobin molecule within red blood cells is
essential for transporting oxygen to the tissues along
with carbon dioxide removal and buffering action
to maintain pH within red cell. Adult haemoglobin
is a 64.4 kDa hetero tetramer comprising of ironcontaining porphyrin called haem and two pairs of
globin polypeptide chains that includes one pair of
alpha and one pair of non-alpha chains. In adults,
96-98 percent haemoglobin A (α2β2) and 2–3.5
percent of haemoglobin A2 (α2δ2) are present. Sickle
haemoglobin (Hb S) is a variant haemoglobin that
results from valine for glutamic acid substitution
at position 6 of β globin chain. Homozygosity for
haemoglobin S (βSβS) causes a serious condition
referred to as ‘sickle cell anemia’. Heterozygosity
for haemoglobin S (ββS), referred to as sickle cell
trait, is usually asymptomatic. The βS gene may also
be co-inherited with another β chain globin variant
e.g. sickle beta thalassaemia. On deoxygenation
and dehydration, HbS solubility is reduced and
irreversible polymerization occurs, causing vascular
obstruction. This phenomenon in vivo has deleterious
effects such as hand–foot syndrome, acute chest
syndrome, cerebral haemorrhage or infarction,
priapism, acute pain crisis, splenic crisis, recurrent
infections and others.

Various diagnostic methods for identification of HbS
include haemoglobin electrophoresis at alkaline and
acidic pH, isoelectric focusing and high performance
liquid chromatography (HPLC). HPLC is one of
the widely utilized methods for HbS detection. On
HPLC, HbS elutes at retention time of 4.5 minutes
(4.30–4.70 minutes) however, a number of other variant
haemoglobins also co-elute at the same retention
time such as Hb Q-Thailand (Mahidol), HbA2´, Hb
Manitoba, HbE- Saskatoon, Hb Montgomery and others.
Therefore, it is essential to identify HbS accurately
in order to differentiate it from other haemoglobins
for proper patient diagnosis and future counseling.
Laboratory accrediting bodies such as College of
American Pathologists (CAP) recommends that if a
patient sample appears to have Hb S in the primary
screening; the laboratory should perform a second
procedure to confirm the presence of Hb S. In order to
fulfill this quality requirement, section of haematology
and transfusion medicine at Aga Khan University
performs sickling test on every patient sample that have
variant haemoglobin in S-window on HPLC. In this test,
patient’s sample is combined with Sodium Metbisulfite
as a reducing agent which causes red cell deoxygenation.
If HbS is present, red cells lose their smooth round
shape and become sickle shaped. The presence of sickle
shaped cells is confirmed by examining the slide under
microscope along with review of both positive and
negative control samples. Very rarely when sickling test
is also negative, we advise patient to confirm presence of
sickle cell disease by molecular testing.
In this way, identification of HbS is confirmed
by two
different
methods and
accurate report
is provided to
patients. Thus,
patient safety
and appropriate
future
management in
ensured.

Patient with Sickle cell trait: A, Leishman stain at 40x showing absence of sickle cells. B, Chromatogram showing variant haemoglobin in S-window.
C, Sodium metbisulfite preparation showing sickling RBCs
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Quality Assurance of Bronchoscopically
Collected Samples
Tazeen Fatima
Resident Clinical Microbiology

Bronchoscopes are medical devices widely used
for diagnostic and therapeutic procedures in a
different variety of patient populations. Flexible
bronchoscopes are critical equipment as they are
introduced in sterile body cavities and should be
decontaminated after each procedure to eliminate
all forms of microbiological life, including
bacterial spores. Appropriate reprocessing of
flexible bronchoscopes is a multistep procedure
involving washing followed by sterilization
or high-level disinfection with further rinsing
and drying before storage. Proper storage is

obligatory. However adequate decontamination
of bronchoscopes is laborious and often
ignored to save resources, time and workload
which has serious implications on patients’
health and can result in bronchoscopy-related
healthcare associated infections, outbreaks and
psuedooutbreaks.
Mycobacterium Tuberculosis, non-tuberculous
mycobacteria (NTM), and Pseudomonas
aeruginosa are the most common pathogens
associated with transmission during bronchoscopy.

Contamination Sources

Inadequate cleaning, disinfection, surface wiping and channel
flushing, use of inadequate detergent/disinfectant (expired, low
potency, resistance of microorganisms)

Use of damaged and leaking scopes and re-use without
decontamination

Improper storage (the scopes must hang down straight), and
inadequate infection control practices and hand hygiene

All images courtesy Google images
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Preanylytical

Potential Sources of Error in Report
Analytical

Postanalytical

1.

1.

1.

2.

Exogenous infectious material
introduced in patient could lead to
bronchoscopically transmitted
infections (increased morbidity and
healthcare cost!)
Collection of poorly representative
and contaminated sample of BAL
(Garbage in garbage out!)

2.

3.

Heavily contaminated samples
(Possibility of missing out true
pathogens!)
Extensive laborious and strenuous
laboratory work (ensuring presence
of true pathogens, identifying pseudo
outbreaks and investigating true
outbreaks)
Increased cost and logistic burden on
labs

Bronchoscopically transmitted infections have grave
consequences on patients’ health and associated
with enormous healthcare costs as positive cases are
often investigated with repeat cultures and advanced
radiological investigations to rule out false positivity.
Those patients are bound to receive unnecessary
antimicrobials until and unless contamination has
been ruled out and also bear adverse effects of
unnecessary treatment. Contaminated bronchoscopy
respiratory samples are a huge burden from
laboratory diagnostic point of view as it requires

2.

Delay in reporting/ communication to
physician from laboratory
Commencement of unwarranted
treatment to patient in case of over
reporting

extensive laboratory work, increased uses of
resources, manpower and time consumption.
Bronchoscopy related infectious complications
reported are rare but the incidence is probably
underestimated, with many episodes unrecognized
and uninformed. Failure of adequate cleaning and
disinfection procedures is the major cause and can
be avoided by proper disinfection/ sterilization,
adequate reprocessing of bronchoscopes and
stringent infection control practices.

Antibody and Reagent QC for Flow
Cytometry Assays
Dr Muhammad Shariq Shaikh and Dr Arsalan Ahmed
Haematology and Histopathology

Flow cytometry is a dynamic technology which
together with specific antibody and fluorochrome
reagents allows to preview at the surface,
cytoplasm and DNA content of thousands of
cells suspended in fluid. It is particularly useful
to determine lineage and potential biologic
behavior of targeted cells. The key feature of this
technology is the use of monoclonal antibodies in
order to ensure epitope specificity. Today, these
antibodies are available from several commercial
suppliers for utilization in diagnostic assays.
These antibodies must go through stringent QC
during manufacturing, distribution, evaluation and
utilization in testing patient samples.
Besides general handling of reagents such as
storage conditions, expiration dates, and “inuse” status, several other factors unique to flow
cytometry reagents are critical in efficient antigenantibody reactions. These factors include: the

quality of the sample, the viability of cells, the pH
of the environment, and the amount of antigen and
antibody available for reaction.
The foremost requirement is validation of
reactivity of each fluorescent-conjugated antibody
before its intended use. The optimal concentration
at which antigen-positive cells can be best
distinguished from nonspecific binding on antigennegative cells should be determined. For instance,
over-expression is an increased number of antigens
per cell and is observed in certain hematological
malignancies. In contrast, weak or dim reactivity
may result from decreased concentration of
antibodies leading to misinterpretation of
results. To resolve this, titration experiments are
performed with variable dilutions. The data is then
analyzed for signal to noise ratio, percentages of
stained and unstained cells and intensity of the
stain.
21
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Additionally, to verify acceptable performance,
all new lots of reagents used in laboratory testing
must be verified against old lots. This includes all
the reagents whether prepared in the laboratory
or purchased from suppliers such as buffers and

lysing reagents. A positive patient sample can
be run concomitantly with the new and old lot
of reagent. Depending on the use of reagents,
acceptability criteria should be established and
achieved results should be documented.

Method Validation: College of American
Pathologists (CAP) requirements of Method
Validation of Quantitative Tests in a Clinical
Laboratory
Dr. Sibtain Ahmed
Chemical Pathology

What is method validation? According to Clinical
& Laboratory Standards Institute (CLSI),
validation is ‘‘The process of testing a measurement
procedure to assess its performance and to determine
whether that performance is acceptable.” The
six elements of method validation are: precision,
Elements

accuracy, reportable range verification, reference
intervals establishment or verification, sensitivity*
and specificity* (*for non FDA approved or
laboratory modified assays). Following table shows
the protocol to be followed in validating a new test
and it should be documented.
How it is Done

Precision
Precision indicates
repeatability, which means,
analyze repeatedly to
determine variation.

To verify inter-assay variation, samples should be processed twice a day in quadruplicate for 5
days producing 20 readings. For intra-assay variation, one sample is run 20 times. Imprecision is
quantified by calculating the mean, standard deviation (SD), and coefficient of variation (CV %) of
data collected from an analytical run

Accuracy
Closeness of the agreement
between test result and
‘‘true’’ result.

Two Approaches : 1. Comparison of results between new method and ‘‘reference’’ method. 2.
Results using new method on certified reference materials or controls.
The first approach is most commonly used. For this run 20 samples within testing range (CLSI
document EP15-A2) by both new and comparative methods. Results are acceptable if the average
bias between the two methods is within allowable limits.

Reportable Range
Analytical Measurement
Range (AMR)
Clinically Reportable Range
(CRR)

AMR (Range of analyte values that a method can directly measure on the specimen, without
any dilution, or other pretreatment) verification must include three levels—low, midpoint, high.
One can use commercial linearity materials, proficiency testing (PT) samples, controls or patient
samples with known results, standards or calibrators. It can also be done by calibration verification,
if three samples that span the measurement range are used. CRR (range of analyte values that are
reported as a quantitative result, allowing for specimen dilution or other pretreatment) is a clinical
decision by the laboratory director/section heads, and does not require experiments or re-validation;
however, dilution or concentration protocols must be specified in methods

Reference Intervals

It is not mandatory but preferable for a laboratory to establish its own reference limit. One can
adopt reference limits from any of the following sources: manufacturer suggested, reference
laboratory, published articles, neighboring laboratory or previous reference limits in the same
laboratory. However reference interval verification is essential for standardized routine analytes.
For verifying reference intervals, we should select 20 representative healthy individuals, and the
test will considered validated if, ≤ 2 of them is outside the manufacturer’s proposed limit. If > 2
outside, can repeat with another 20, and accept if ≤ 2 is outside.
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Meeting Report of International Federation of
Clinical Chemistry (IFCC) Conferences- 2017
Reported by Dr Sibtain Ahmed and Dr Hafsa Majid
Clinical Chemistry

This year International
Federation of Clinical
Chemistry (IFCC) organized
two events at Durban South
Africa: XIVth International
Congress of Paediatric
Laboratory Medicine (ICPLM)
and International Congress
of Clinical Chemistry and
Laboratory Medicine, Worldlab.
The ICPLM was organized by
the Task Force on Paediatric
Laboratory Medicine (TFPLM) in cooperation with the
African Federation of Clinical
Chemistry (AFCC), on 20-21st
Figure 1: Participants from Pakistan at ICPLM & IFCC-Worldlab 2017
October 2017. International
Congress of Clinical Chemistry and Laboratory
conferences high quality scientific programs
Medicine, Worldlab was organized in partnership
were arranged. The plenary sessions covered
with South African Association for Clinical
wide range of topics ranging from innovations
Biochemistry (SAACB) and AFCC, from October
in techniques, neonatal and newborn screening,
22nd to 25th 2017.
evidence based laboratory medicine, laboratory
accreditation, incidence and spectrum of inherited
One of the goals of the IFCC is to identify and
metabolic diseases in South Africa, application
nurture talented young scientists and increase
of big data, standardization, reference intervals
participation of pathologists from developing
establishment and risk management.
countries. The IFCC achieves this goal by
giving travel grants to its member societies
The conference attracted people from many
from different countries. This year Dr Hafsa
countries and continents and provided an eclectic
Majid and Dr Sibtain Ahmed were awarded
mix of topics relevant to Clinical Chemistry
these scholarships from Pakistan. Dr Sibtain
including practical overview of latest advances
Ahmed also received 2nd best prize for poster
in the field of laboratory medicine. To conclude,
presentation on abstract regarding neonatal
this was an overwhelming and rewarding
TSH reference interval in Pakistan. In both
experience.
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